Table 1. Patients’ characteristics at baseline of the original JPAD trial.
| Aspirin | No aspirin | P value | |
|---|---|---|---|
| N | 1075 | 1098 | |
| Age, y | 65 ± 10 | 64 ± 10 | 0.01 |
| Male | 592 (55) | 573 (52) | 0.2 |
| BMI, kg/m2 | 24 ± 4 | 24 ± 4 | 0.4 |
| Duration of diabetes, y | 7.2 (2.8–12.2) | 6.5 (2.9–12.1) | 0.4 |
| Hypertension | 604 (56) | 605 (55) | 0.6 |
| Dyslipidemia | 578 (54) | 568 (52) | 0.3 |
| History of smoking | 234 (22) | 210 (19) | 0.1 |
| Systolic BP, mmHg | 135 ± 15 | 134 ± 14 | 0.06 |
| Diastolic BP, mmHg | 77 ± 9 | 76 ± 9 | 0.03 |
| FPG, mmol/L | 8.1 ± 2.7 | 8.0 ± 2.6 | 0.7 |
| HbA1c, % | 7.5 ± 1.4 | 7.4 ± 1.2 | 0.09 |
| Serum creatinine, μmol/L | 0.77 ± 0.22 | 0.75 ± 0.20 | 0.04 |
| eGFR, ml/min/1.73m2 | 74.0 ± 19.3 | 75.6 ± 20.0 | 0.06 |
| Total cholesterol, mmol/L | 5.22 ± 0.88 | 5.17 ± 0.88 | 0.1 |
| Fasting triglycerides, mmol/L | 1.28 (0.89–1.78) | 1.25 (0.89–1.81) | 0.5 |
| HDL cholesterol, mmol/L | 1.45 ± 0.41 | 1.45 ± 0.39 | 0.9 |
| Medications | |||
| Sulfonylurea | 619 (58) | 604 (55) | 0.2 |
| α-glycosidase inhibitor | 353 (33) | 363 (33) | 0.9 |
| Biguanide | 134 (12) | 156 (14) | 0.2 |
| Thiazolidinedione | 51 (5) | 49 (4) | 0.8 |
| Insulin | 138 (13) | 130 (12) | 0.5 |
| Calcium channel blocker | 344 (32) | 358 (33) | 0.8 |
| ACE inhibitor | 145 (13) | 159 (14) | 0.5 |
| ARB | 209 (19) | 210 (19) | 0.9 |
| β-blocker | 61 (6) | 76 (7) | 0.2 |
| Statin | 266 (25) | 292 (27) | 0.3 |
Duration of diabetes and fasting triglyceride levels are expressed as medians (interquartile range). BMI indicates body mass index; BP, blood pressure; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate; HDL, high- density lipoprotein; ACE, angiotensin-converting enzyme; and ARB, angiotensin II type 1 receptor blocker.